Skip to main content

Table 4 Results of the population subgroups according to the risk factors associated

From: Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

 

Population subgroup A

Population subgroup B

Population subgroup C

 

Non-prophylaxis

Palivizumab

Incremental palivizumab vs non-prophylaxis.

Non-prophylaxis

Palivizumab

Incremental palivizumab vs non-prophylaxis.

Non-prophylaxis

Palivizumab

Incremental palivizumab vs non-prophylaxis.

Effectiveness

 QALYs

5.16

5.25

0.0889

5.18

5.26

0.0821

5.18

5.26

0.0822

Costs

 Total costs

€1,589.57

€2,616.92

€1,027.34

€1,088.90

€2,252.69

€1,163.79

€1,063.23

€2,209.48

€1,146.25

 Prophylaxis costs

€0.00

€1,886.78

€1,886.78

€0.00 €

€1,886.78

€1,886.78

€0.00

€1,886.78

€1,886.78

 Hospital related costsa

€1,105.98 €

€571.02

€-534.96

€637.14

€216.39

€-420.75

€613.10

€174.31

€-438.79

 Recurrent wheezing costs

€483.59

€159.11

€-324.48

€451.76

€149.52 €

€-302.24

€450.13

€148.38

€-301.74

ICUR (€/QALY gained)

11,550.37

14,177.18

13,937.61

  1. QALY: Quality adjusted life years; Subgroup A: 2 major risk factors and 2 minor risk factors; Subgroup B: 2 major factors and 1 minor factor; Subgroup C: 2 major factors; Major factors included chronological age less than10 weeks at the beginning of RSV season or being born during the first 10 weeks of the season; school-age siblings or day-care attendance whereas minor factors included mother smoking during pregnancy and male gender [33]. Major factors: chronological age less than 10 weeks at the beginning of RSV season or being born during the first 10 weeks of the season; school-age siblings or day-care attendance. Minor factors: mother smoking during pregnancy and male gender
  2. aHospital related costs included emergency visit prior hospitalization cost, hospital and ICU admission costs